Publication: BRAF inhibitor treatment of classical hairy cell leukemia allows successful vaccination against SARS-CoV-2
BRAF inhibitor treatment of classical hairy cell leukemia allows successful vaccination against SARS-CoV-2
Date
Date
Date
Citations
Konrat, J., Rösler, W., Roiss, M., Meier-Abt, F., Widmer, C. C., Balabanov, S., Manz, M. G., & Zenz, T. (2023). BRAF inhibitor treatment of classical hairy cell leukemia allows successful vaccination against SARS-CoV-2. Annals of Hematology, 102, 403–406. https://doi.org/10.1007/s00277-022-05026-z
Abstract
Abstract
Abstract
In classical hairy cell leukemia (HCL), standard treatments including purine analogs achieve a durable response (up to 90%), but lead to severe immunosuppression and long-lasting depletion of CD4 + T lymphocytes. The BRAF inhibitor vemurafenib is effective in HCL, but its use in first-line treatment is restricted to select clinical situations (e.g. active infection). Its impact on immune function or response to vaccines in HCL is unclear. We treated four HCL patients with vemurafenib during the COVID-19 pandemic and monitored immune r
Metrics
Downloads
Views
Additional indexing
Creators (Authors)
- Konrat, Judith
- Rösler, Wiebke
- Roiss, Michael
- Meier-Abt, Fabienne
- Widmer, Corinne C
- Balabanov, Stefan
- Manz, Markus G
- Zenz, Thorsten
Volume
Volume
Volume
Number
Number
Number
Page range/Item number
Page range/Item number
Page range/Item number
Page end
Page end
Page end
Item Type
Item Type
Item Type
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Free Access at
Free Access at
Free Access at
Publisher DOI
Metrics
Downloads
Views
Citations
Konrat, J., Rösler, W., Roiss, M., Meier-Abt, F., Widmer, C. C., Balabanov, S., Manz, M. G., & Zenz, T. (2023). BRAF inhibitor treatment of classical hairy cell leukemia allows successful vaccination against SARS-CoV-2. Annals of Hematology, 102, 403–406. https://doi.org/10.1007/s00277-022-05026-z
